Practical application of biochemical failure definitions: What to do and when to do it

International Journal of Radiation Oncology Biology Physics

Volumn 53, Issue 2, 2002, Pages 304-315

  Kestin, Larry L ^a   Vicini, Frank A ^a   Martinez, Alvaro A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Biochemical failure; Prostate; Prostate specific antigen; Prostatic neoplasms; Radiotherapy

Indexed keywords

ANTIGENS; CORRELATION METHODS; TUMORS;

BIOCHEMICAL FAILURE;

RADIOTHERAPY;

NADIR; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; SENSITIVITY AND SPECIFICITY;

EID: 0036603598     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02707-4     Document Type: Article

References (61)

1. Modeling postradiation prostate specific antigen level kinetics: Predictors of rising postnadir slope suggest cure in men who remain biochemically free of prostate carcinoma
2. Patterns and fate of PSA bouncing following 3D-CRT
3. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer
4. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer
5. Caution in interpreting biochemical control rates after treatment of prostate cancer: Length of follow-up influences results
6. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy
7. Statistical aspects of evaluating treatment and prognostic factors for clinically localized prostate cancer
8. Biological variation of prostate specific antigen levels in serum: An evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients
9. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer
10. The effect of pelvic radiation therapy on serum levels of prostate specific antigen
11. The long-term effect on PSA values of incidental prostatic irradiation in patients with pelvic malignancies other than prostate cancer
12. Consensus statement. Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel
13. Prostate-specific antigen (PSA) best practice policy
14. Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy
15. Serum prostate-specific antigen profile following radiotherapy for prostate cancer: Implications for patterns of failure and definition of cure
16. A method for determining a prostate-specific antigen cure after radiation therapy for clinically localized prostate cancer
17. Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy
18. Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. American Society for Therapeutic Radiology and Oncology
19. The impact of irregularly rising prostate-specific antigen and "impending failure" on the apparent outcome of localized prostate cancer following radiotherapy
20. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control
21. PSA-based outcome analysis after radiation therapy for prostate cancer: A new definition of biochemical failure after intervention
22. The definition of biochemical failure in patients treated with definitive radiotherapy
23. PSA relapse definitions - The Vancouver Rules show superior predictive power
24. Definitions of biochemical failure in prostate cancer following radiation therapy
25. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma
26. The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer
27. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate
28. Prostate
29. Nonparametric estimation from incomplete observations
30. Evaluation of survival data and two new rank order statistics arising in its consideration
31. Regression models and life-tables
32. Prostatic-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling time
33. Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen
34. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer
35. Natural history of progression after PSA elevation following radical prostatectomy
36. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: Correlation with histologic characteristics of the primary cancer
37. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer
38. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy
39. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy
40. Immediate versus deferred treatment for advanced prostatic cancer. Initial results of the Medical Research Council Trial
41. Immediate vs. deferred hormone treatment for prostate cancer: How safe is androgen deprivation? Medical Research Council Prostate Cancer Working Party Investigators Group
42. Proceedings. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate
43. VACURG studies of conservative treatment
44. Quality of life issues relating to endocrine treatment options
45. Endocrine treatment of prostate cancer: Recent developments and the future. Part I: Maximal androgen blockage, early vs. delayed endocrine treatment and side-effects
46. A structured debate: Immediate versus deferred androgen suppression in prostate cancer - Evidence for deferred treatment
47. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
48. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized study
49. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy
50. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer
51. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate
52. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
53. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate
54. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: Long-term results of a prospective randomized study
55. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression
56. Neoadjuvant treatment before radical prostatectomy decreases the number of positive margins in cT2-T3 but has no impact on PSA progression or survival in cT2-T3
57. Neoadjuvant hormone therapy: The Canadian trials
58. Radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in cT2b prostate cancer - 24 month results
59. Neoadjuvant combined androgen deprivation therapy in locally confined prostatic carcinoma: 3 to 4 years of follow-up of a European randomized study
60. RTOG protocol 92-02: A phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate